Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262287 · ClinicalTrials.gov registry record · Phase 4
Dutasteride for the Reduction of Alcohol Use in Male Drinkers
A Phase 4 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT01262287 is a Phase 4 study that has completed, run by UConn Health. The registered enrollment target is 47 participants.
The verdict
NCT01262287, a Phase 4 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether dutasteride is safe and effective for reducing alcohol use in male drinkers who want to stop or reduce their drinking. The investigators hypothesize that at a dosage of 1mg/day, dutasteride will be well tolerated and that, compared to placebo treatment, dutasteride will result in a greater reduction in the amount of alcohol consumed per week. The study sample size is of a pilot scale and is designed to provide additional support for the study hypothesis and provide an estimate of likely effect sizes in order to design a more definitive study.
Interventions
- DRUG Placebo
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262287
The ClinicalTrials.gov registry entry for NCT01262287 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01262287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262287 about?
NCT01262287 is a clinical study titled "Dutasteride for the Reduction of Alcohol Use in Male Drinkers". The purpose of this study is to evaluate whether dutasteride is safe and effective for reducing alcohol use in male drinkers who want to stop or reduce their drinking. The investigators hypothesize that at a dosage of 1mg/day, dutasteride will be well tolerated and that, compared to placebo treatmen...
What is the current status of trial NCT01262287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2011-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01262287?
The interventions under investigation include: Placebo (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT01262287?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.